7th Glioblastoma Drug Development Summit

Innovating Novel Combination Therapies and Maximising Preclinical and Clinical Development to Improve Glioblastoma Targeting and Increase Investment Opportunities to Ultimately Bring Efficacious Therapies to Patients in Need
The glioblastoma drug development space has been energized by Merck's acquisition of Modifi Bio last December. This landmark deal has sparked renewed hope in a field long challenged by limited investment and clinical breakthroughs.

Looking ahead to 2026, it's crucial to sustain this momentum. The 7th Glioblastoma Drug Development Summit is your essential platform for accelerating new treatments and continuing this vital progress.

Join us for a definitive, 3-day summit designed to accelerate progress. With groundbreaking content and six deep-dive workshops, you'll connect with over 90 leading experts from every corner of the field - from biotech to investment. This is your opportunity to uncover the latest advancements, learn how to overcome funding challenges, and explore the transformative role of AI in glioblastoma.

Together, we'll unlock actionable insights, forge powerful partnerships, and secure the future of your pipeline and move towards the delivery of transformative therapies for one of the most devastating and underserved cancers.

URLs:
Website: https://go.evvnt.com/3272717-0?pid=2874
Brochure: https://go.evvnt.com/3272717-3?pid=2874
Twitter: https://go.evvnt.com/3272717-4?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Industry Pricing - Conference Only: USD 2999.00,
Industry Pricing - Conference + Workshop Day: USD 4197.00,
Academic Pricing - Conference Only: USD 2599.00,
Academic Pricing - Conference + Workshop Day: USD 3597.00,
Service Provider Pricing - Conference Only: USD 3699.00,
Service Provider Pricing - Conference + Workshop Day: USD 5097.00

Speakers: Do-Hyun Nam Founder and Chief Executive Officer Aimed Bio Inc., Mykola Zdioruk Senior Scientist AstraZeneca, John Higgins Managing Director Brain Tumor Investment Fund, Francesca Barone Chief Scientific Officer Candel Therapeutics, Saskia Biskup Managing Director CeGaT GmbH, Sandra Silberman Chief Medical Officer CNS Pharmaceuticals, Liisi Laaniste Chief Scientific Offier CoSyne Therapeutics, Ulrike Gerdemann Principal Investigator and Physician Scientist Dana-Farber Cancer Institute, Kimberly Lindstrom Senior Vice President - Regulatory Science and Gcp Quality Day One Biopharmaceuticals, Inc., Carlo Russo Chief Medical Officer and Head of Development Genenta Science, Sam Blackman Entrepreneur-in-Residence Google Ventures, Zohreh Amoozgar Visiting Scientist Harvard Medical School, Jianping Huang CEO Immunogenik, Aaron Edwards CEO and Co-Founder KiraGen Bio, Victoria Llado Canellas Chief Strategy Officer Laminar Pharma Inc, Panna Sharma Chief Executive Officer and President Lantern Pharma, Fahar Merchant Chief Executive Officer Medicenna Therapeutics, Carla Bauer Director - Oncology Search and Evaluation, Business Development and Licensing Merck and Co, Jason Binder Head of Patient Experience Pathos AI, Jonathan Pritz Investment Director RA Capital Management, Daniel Yokell Vice President - Theranostic NeuroOncology Telix Pharmaceuticals, David Tran Chief, Associate Professor and Co-Director - Neuro-Oncology, Neurological Surgery and Neurology University of Southern California, David E Anderson Chief Scientific Officer VBI Vaccines and HDT Bio, Yash Thukral Founding Partner White Lion Capital LLC, Ranjit Bindra Professor Yale Univerisity